- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.06. | Novartis' ribociclib approved in Canada for early breast cancer | ||
| 20.06. | FDA cell and gene therapy director exit increases 'volatility' for sector | ||
| 20.06. | NSW government invests $13.39m in life-changing therapies | ||
| 20.06. | DoH - Abu Dhabi and Sanofi link for vaccine development | ||
| 19.06. | CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024 | ||
| 19.06. | UK and US governments pursue contrasting vaccine strategies | ||
| 19.06. | Actio gains $66m to advance small molecule therapeutics pipeline | ||
| 19.06. | BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals | ||
| 19.06. | Eli Lilly and Eisai's Alzheimer's drugs denied NHS use due to high costs | ||
| 19.06. | Draig secures $140m for neuropsychiatric disorder therapies | ||
| 19.06. | Gilead Sciences' Yeztugo receives approval from US FDA for HIV | ||
| 18.06. | Bavarian Nordic nets $160m from priority review voucher sale | ||
| 18.06. | Tisento's MELAS treatment receives fast track status from FDA | ||
| 18.06. | FDA Commissioner envisions fewer delays, more clinical trial flexibility and AI use | ||
| 18.06. | Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade | ||
| 18.06. | Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes | ||
| 18.06. | Orion and Glykos extend ADC collaboration | ||
| 18.06. | FDA creates new priority review voucher scheme to boost US interests | ||
| 18.06. | Lisata collaborates with GATC Health on drug development | ||
| 18.06. | Genomics to roll out predictive clinical test across UK | ||
| 17.06. | Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn | ||
| 17.06. | AI-powered orchestration: Bringing the benefits to personalized therapy | ||
| 17.06. | European pharma needs scalable models to succeed in US | ||
| 17.06. | Averoa secures EC authorisation for oral CKD treatment | ||
| 17.06. | European biotech ecosystem takes aim at changing the funding narrative |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .